2024-11-24 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

Vertex Pharmaceuticals Inc. (VRTX) is a biotechnology company focused on the discovery, development and commercialization of innovative medicines for serious diseases.

The cumulative return of VRTX is 166.65%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 127.58%.  The difference is 39.07%, placing it in the 66.43rd percentile of its historical performance range relative to the S&P 500 (based on a minimum difference of -69.76% and a maximum of 94.07%).

**Alpha and Beta Analysis:**

The provided data shows varying alpha and beta values across different time periods.  While alpha (outperformance relative to the market) has generally been positive, indicating above-market returns, it has fluctuated considerably. Beta, a measure of volatility relative to the market, has decreased over time, suggesting reduced market sensitivity.  This suggests periods of high outperformance (like 2017-2019) were followed by periods of lower, more market-correlated returns.  Cap(B) indicates a consistently growing market capitalization.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 21.8% | 32.2% | -16.6% | 1.6 | 38.6 |
| 2016-2018  | 34.8% | 31.5% | 2.5% | 1.5 | 42.7 |
| 2017-2019  | 192.4% | 19.1% | 140.7% | 1.2 | 56.4 |
| 2018-2020  | 54.6% | 30.4% | 7.2% | 0.9 | 60.9 |
| 2019-2021  | 33.8% | 34.7% | -66.2% | 0.8 | 56.5 |
| 2020-2022  | 31.6% | 34.7% | 8.0% | 0.7 | 74.4 |
| 2021-2023  | 77.3% | 21.3% | 42.4% | 0.6 | 104.8 |
| 2022-2024  | 102.7% | 18.8% | 72.6% | 0.6 | 116.0 |


**2. Recent Price Movement:**

* **Closing Price:** 450.97
* **5-Day Moving Average:** 453.52
* **20-Day Moving Average:** 477.9
* **60-Day Moving Average:** 474.56

The stock price is currently below its 5, 20, and 60-day moving averages, suggesting a downward trend in the short to medium term.

**3. Technical Indicators:**

* **RSI (42.3):**  Approaching oversold territory (below 30), suggesting potential for a bounce.
* **PPO (-1.11):** Negative value indicates bearish momentum.
* **Relative Strength Change (20-day):** -13.77%, indicating a recent decrease in relative strength.

The combination of a low RSI and negative PPO suggests a bearish sentiment, but the oversold RSI could signal a short-term rebound.  The significant difference between the current price and the moving averages, however, suggests a possibility of further downward pressure.  Given the current price of 450.95 is close to the 5-day moving average and well below other averages, there is no significant immediate 

**4. Recent Earnings and Outlook:**

The earnings data shows significant variability. While Q3 2024 shows positive EPS and revenue, some quarters show substantial losses (e.g., Q2 2024).  Further information, including earnings expectations for the periods shown, is needed for a more complete assessment.  The provided data alone does not allow a robust assessment of the company's future.

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-11-05 | 4.05    | 2.77 B$      |
| 2024-08-02 | -13.92  | 2.65 B$      |
| 2024-05-07 | 4.26    | 2.69 B$      |
| 2023-11-07 | 4.01    | 2.48 B$      |
| 2024-11-05 | 4.01    | 2.48 B$      | *(Duplicate entry)*


**5. Financial Information:**

* **Revenue and Profitability:**  The company shows consistent high profit margins (around 85-87%), indicating strong revenue generation and efficiency. However, ROE fluctuates considerably, highlighting potential volatility in profitability.


* **Capital and Profitability:**  Equity shows variability, and ROE demonstrates periods of both strong profitability and significant losses, consistent with the EPS data.  This underscores the need for more comprehensive analysis of profitability drivers and risk factors.


**6. News and Recent Issues:**

* *Information needed:*  Please provide details on recent news (within the last two days) including earnings news from sources like Shacknews or financial news outlets.  This section requires specific news articles to be properly analyzed.

**7. Analyst Opinions and Performance Highlights:**

* *Information needed:* Details on recent market outlook and analyst opinions from sources like FINBOLD or other reputable financial analysis firms are required for a complete analysis.


**8. Overall Summary:**

VRTX has shown significant long-term outperformance compared to the S&P 500, but its recent performance indicates a potential short-term downturn.  While the company exhibits strong profit margins, the volatility in earnings and ROE highlights some risks.  A comprehensive analysis requires further information on recent news, analyst opinions, and detailed explanation of the significant EPS fluctuations.  The current technical indicators suggest a bearish short-term outlook, although the low RSI hints at potential short-term recovery. A long-term outlook (2+ years) remains positive, given its historical performance and potential long-term growth opportunities, assuming underlying business performance remains strong.  Further fundamental and technical analysis, along with news and analyst commentary, are crucial before making any investment decisions.


**9. Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice.  Investing involves risk, and past performance does not guarantee future results.  Consult with a qualified financial advisor before making any investment decisions.
